Microtubules as a target for anticancer drugs

Nature Reviews Cancer

Volumn 4, Issue 4, 2004, Pages 253-265

  Jordan, Mary Ann ^a   Wilson, Leslie ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; ANTINEOPLASTIC AGENT; AURISTATIN PE; AVE 8029; AVE 80629; COLCHICINE; CRYPTOPHYCIN 52; DISCODERMOLIDE; DOCETAXEL; E 7389; ESTRAMUSTINE; IXABEPILONE; LANLIMALIDE; MAYTANSINE; N ACETYLCOLCHINOL PHOSPHATE; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; NAVELBINE; NOSCAPINE; PACLITAXEL; PODOPHYLLOTOXIN; RHAZINALAM; RHIZOXIN; SPONGISTATIN 1; TALTOBULIN; TL 00139; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINFLUNINE;

APOPTOSIS; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CELL ACTIVITY; CLINICAL TRIAL; CONCENTRATION RESPONSE; CYTOSKELETON; DEPOLYMERIZATION; DRUG ACTIVITY; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; DYNAMICS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MICROTUBULE; MITOSIS SPINDLE; NEUROTOXICITY; PERIPHERAL NEUROPATHY; POLYMERIZATION; PRIORITY JOURNAL; REVIEW; TOXICITY; TUMOR VASCULARIZATION;

EID: 1942438028     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1317     Document Type: Review

References (168)

1. Luduena, R. F. Multiple forms of tubulin: different gene products and covalent modifications. Int. Rev. Cytology 178, 207-275 (1998). Comprehensive review of tubulin isotypes and post-translational modifications.
2. Verdier-Pinard, P. et al. Direct analysis of tubulin expression in cancer cell lines by electrospray ionization mass spectrometry. Biochemistry 42, 12019-12027 (2003). Describes analysis of tubulin isotypes, mutations and post-translational modifications by liquid chromatography/electrospray-ionization mass spectrometry in paclitaxel-sensitive and -resistant cell lines.
3. Ligon, L. A., Shelly, S. S., Tokito, M. & Holzbaur, E. L. The microtubule plus-end proteins EB1 and dynactin have differential effects on microtubule polymerization. Mol. Biol. Cell 14, 1405-1417 (2003).
4. Galmarini, C. M. et al. Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics. Br. J. Cancer 88, 1793-1799 (2003).
5. Giodini, A. et al. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res. 62, 2462-2467 (2002).
6. Cassimeris, L. The oncoprotein 18/stathmin family of microtubule destabilizers. Curr. Opin. Cell Biol. 14, 18-24 (2002).
7. Spittle, C., Charrasse, S., Larroque, C. & Cassimeris, L. The interaction of TOGp with microtubules and tubulin. J. Biol. Chem. 275, 20748-20753 (2000).
8. Maney, T., Wagenbach, M. & Wordeman, L. Molecular dissection of the microtubule depolymerizing activity of mitotic centromere-associated kinesin. J. Biol. Chem. 276, 34753-34758 (2001).
9. Jordan, M. A. & Wilson, L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr. Opin. Cell Biol. 10, 123-130 (1998).
10. Giannakakou, P., Sackett, D. & Fojo, T. Tubulin/microtubules: still a promising target for new chemotherapeutic agents. J. Natl Cancer Inst. 92, 182-183 (2000).
11. Gerzon, K. in Anticancer Agents Based on Natural Product Models (eds Cassady, J. M. & Douros, J. D.) 271-317 (Academic, New York, 1980).
12. Wordeman, L. & Mitchison, T. J. In Microtubules (eds Hyams, J. S. & Lloyd, C. W.) 287-302 (Wiley-Liss, New York, 1994).
13. Wilson, L. & Jordan, M. A. in Microtubules (eds Hyams, J. S. & Lloyd, C. W.) 59-84 (Wiley-Liss, New York, 1994).
14. McIntosh, J. R. in Microtubules (eds Hyams, J. S. & Lloyd, C. W.) 413-434 (Wiley-Liss, New York, 1994).
15. Waterman-Storer, C. & Salmon, E. D. Microtubule dynamics: treadmilling comes around again. Curr. Biol. 7, 369-372 (1997).
16. Mitchison, T. J. & Kirschner, M. Dynamic instability of microtubule growth. Nature 312, 237-242 (1984).
17. Margolis, R. L. & Wilson, L. Opposite end assembly and disassembly of microtubules at steady state in vitro. Cell 13, 1-8 (1978).
18. Margolis, R. L. & Wilson, L. Microtubule treadmilling: what goes around comes around. Bioessays 20, 830-836 (1998).
19. Rodionov, V. I. & Borisy, G. G. Microtubule treadmilling in vivo. Science 275, 215-218 (1997).
20. Shaw, S. L., Kamyar, R. & Ehrhardt, D. W. Sustained microtubule treadmilling in Arabidopsis cortical arrays. Science 300, 1715-1718 (2003).
21. Panda, D., Miller, H. P. & Wilson, L. Rapid treadmilling of MAP-free brain microtubules in vitro and its suppression by tau. Proc. Natl Acad. Sci. USA 96, 12459-12464 (1999).
22. Chen, W. & Zhang, D. Kinetochore fibre dynamics outside the context of the spindle during anaphase. Nature Cell Biol. 6, 227-231 (2004). Demonstration of importance of treadmilling in anaphase-chromosome poleward movement and the independence of treadmilling from the spindle matrix.
23. Wilson, L., Panda, D. & Jordan, M. A. Modulation of microtubule dynamics by drugs: a paradigm for the actions of cellular regulators. Cell Struct. Funct. 24, 329-335 (1999).
24. Nogales, E. Structural insights into microtubule function. Annu. Rev. Biophys. Biomol. Struct. 30, 397-420 (2001).
25. Wilson, L. & Jordan, M. A. Microtubule dynamics: taking aim at a moving target. Chem. Biol. 2, 569-573 (1995).
26. Lodish, H. et al. Molecular Cell Biology (W. H. Freeman, New York, 1999).
27. Panda, D., Miller, H. & Wilson, L. Determination of the size and chemical nature of the stabilizing cap at microtubule ends using modulators of polymerization dynamics. Biochemistry 41, 1609-1617 (2002).
28. Caplow, M. & Fee, L. Concerning the chemical nature of tubulin subunits that cap and stabilize microtubules. Biochemistry 42, 2122-2126 (2003).
29. Panda, D., Miller, H. P. & Wilson, L. Rapid treadmilling of brain microtubules free of microtubule-associated proteins in vitro and its suppression by tau. Proc. Natl Acad. Sci. USA 96, 12459-12464 (1999).
30. Wittmann, T., Bokoch, G. & Waterman-Storer, C. Regulation of leading edge microtubule and actin dynamics downstream of Rac1. J. Cell Biol. 161, 845-851 (2003).
31. Alli, E., Bash-Babula, J., Yang, J.-M. & Hait, W. N. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res. 62, 6864-6869 (2002).
32. McNally, F. Microtubule dynamics: new surprises from an old MAP. Curr. Biol. 13, 597-599 (2003).
33. Ohi, R., Coughlin, M. L., Lane, W. S. & Mitchison, T. J. An inner centromere protein that stimulates the microtubule depolymerizing activity of a Kin1 kinesin. Dev. Cell 5, 309-321 (2003).
34. Carvalho, P., Tirnauer, J. & Pellman, D. Surfing on microtubule ends. Trends Cell Biol. 13, 229-237 (2003).
35. Hergovich, A., Lisztwan, J., Barry, R., Ballschmieter, P. & Krek, W. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nature Cell Biol. 5, 64-70 (2003).
36. Komarova, Y., Akhmanova, A., Kojima, S., Galjart, N. & Borisy, G. Cytoplasmic linker proteins promote microtubule rescue in vivo. J. Cell Biol. 159, 589-599 (2002).
37. Mitchison, T. J. Microtubule dynamics and kinetochore function in mitosis. Annu. Rev. Cell Biol. 4, 527-549 (1988).
38. Saxton, W. M. et al. Tubulin dynamics in cultured mammalian cells. J. Cell Biol. 99, 2175-2186 (1984).
39. Rusan, N. M., Fagerstrom, C. J., Yvon, A.-M. C. & Wadsworth, P. Cell cycle-dependent changes in microtubule dynamics in living cells expressing green fluorescent protein-α tubulin. Mol. Biol. Cell 12, 971-980 (2001).
40. Pepperkok, R., Bre, M. H., Davoust, J. & Kreis, T. E. Microtubules are stabilized in confluent epithelial cells but not in fibroblasts. J. Cell Biol. 111, 3003-3012 (1990).
41. Zhai, Y., Kronebusch, P. J., Simon, P. M. & Borisy, G. G. Microtubule dynamics at the G2/M transition: abrupt breakdown of cytoplasmic microtubules at nuclear envelope breakdown and implications for spindle morphogenesis. J. Cell Biol. 135, 201-214 (1996).
42. Hayden, J. J., Bowser, S. S. & Rieder, C. Kinetochores capture astral microtubules during chromosome attachment to the mitotic spindle: direct visualization in live newt cells. J. Cell Biol. 111, 1039-1045 (1990). Classic demonstration of the role of microtubule dynamic instability in the attachment of chromosomes to the mitotic spindle.
43. Jordan, M. A. et al. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 56, 816-825 (1996). Demonstration that mitotic block by low concentrations of paclitaxel leads to apoptosis.
44. Rieder, C., Schultz, A., Cole, R. & Sluder, G. Anaphase onset in vertebrate somatic cells is controlled by a checkpoint that monitors sister kinetochore attachment to the spindle. J. Cell Biol. 127, 1301-1310 (1994).
45. Shelby, R. D., Hahn, K. M. & Sullivan, K. F. Dynamic elastic behavior of α-satellite DNA domains visualized in situ in living human cells. J. Cell Biol. 135, 545-557 (1996).
46. Mitchison, T. J. Poleward microtubule flux in the mitotic spindle; evidence from photoactivation of fluorescence. J. Cell Biol. 109, 637-652 (1989).
47. Wilson, P. J. & Forer, A. Effects of nanomolar taxol on cranefly spermatocyte spindles indicate that acetylation of kinetochore microtubules can be used as a marker of poleward tubulin flux. Cell Motil. Cytoskeleton 37, 20-32 (1997).
48. Li, X. & Nicklas, R. B. Mitotic forces control a cell-cycle checkpoint. Nature 373, 630-632 (1995).
49. Nicklas, R. B., Ward, S. C. & Gorbsky, G. J. Kinetochore chemistry is sensitive to tension and may link mitotic forces to a cell cycle checkpoint. J. Cell Biol. 130, 929-939 (1995).
50. Gorbsky, G. J. Cell cycle checkpoints: arresting progress in mitosis. BioEssays 19, 193-197 (1997).
51. Zhou, J. et al. Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation. Mol. Pharmacol. 63, 799-807 (2003).
52. Hamel, E. & Covell, D. G. Antimitotic peptides and depsipeptides. Curr. Med. Chem. Anti-Canc. Agents 2, 19-53 (2002).
53. Hoffman, J. C. & Vaughn, K. C. Mitotic disrupter herbicides act by a single mechanism but vary in efficacy. Protoplasma 179, 16-25 (1994).
54. Lacey, E. & Gill, J. H. Biochemistry of benzimidazole resistance. Acta Trop. 56, 245-262 (1994).
55. Lobert, S., Ingram, J. & Correia, J. Additivity of dilantin and vinblastine inhibitory effects on microtubule assembly. Cancer Res. 59, 4816-4822 (1999).
56. Cann, J. R. & Hinman, N. D. Interaction of chlorpromazine with brain microtubule subunit protein. Molec. Pharmacol. 11, 256-267 (1975).
57. Boder, G. B., Paul, D. C. & Williams, D. C. Chlorpromazine inhibits mitosis of mammalian cells. Eur. J. Cell Biol. 31, 349-353 (1983).
58. Jordan, M. A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr. Med. Chem. Anti-Canc. Agents 2, 1-17 (2002).
59. Jimenez-Barbero, J., Amat-Guerri, F. & Snyder, J. P. The solid state, solution and tubulin-bound conformations of agents that promote microtubule stabilization. Curr. Med. Chem. Anti-Canc. Agents 2, 91-122 (2002).
60. Jordan, M. A., Toso, R. J., Thrower, D. & Wilson, L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc. Natl Acad. Sci. USA 90, 9552-9556 (1993).
61. Chen, J.-G. & Horwitz, S. B. Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. Cancer Res. 62, 1935-1938 (2002).
62. Yvon, A.-M., Wadsworth, P. & Jordan, M. A. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol. Biol. Cell 10, 947-949 (1999). First demonstration that suppression of microtubule dynamics in living cells by low concentrations of paclitaxel correlates with mitotic block.
63. Jordan, M. A. & Wilson, L. in Methods in Cell Biology, in Mitosis and Meiosis Vol. 61 (ed. Rieder, C. L.) 267-295 (Academic, New York, 1998).
64. Skibbens, R. V., Skeen, V. P. & Salmon, E. D. Directional instability of kinetochore motility during chromosome congression and segregation in mitotic newt lung cells: a push-pull mechanism. J. Cell Biol. 122, 859-875 (1993).
65. Waters, J. C., Mitchison, T. J., Rieder, C. L. & Salmon, E. D. The kinetochore microtubule minus-end disassembly associated with poleward flux produces a force that can do work. Mol. Biol. Cell 7, 1547-1558 (1996).
66. Johnson, I. S., Wright, H. F. & Svoboda, G. H. Experimental basis for clinical evaluation of anti-tumor principles derived from Vinca rosea Linn. J. Lab. Clin. Med. 54, 830-837 (1959).
67. Noble, R. L., Beer, C. T. & Cutts, J. H. Further biological activities of vincaleukoblastine: an alkaloid isolated from Vinca rosea (L.). Biochem. Pharmacol. 1, 347-348 (1958).
68. Gidding, C. E., Kellie, S. J., Kamps, W. A. & de Graaf, S. S. Vincristine revisited. Crit. Rev. Oncol. Hematol. 29, 267-287 (1999).
69. Quasthoff, S. & Hartung, H. P. Chemotherapy-induced peripheral neuropathy. J. Neurol. 249, 9-17 (2002).
70. Sahenk, Z., Barohn, R., New, P. & Mendell, J. R. Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings. Arch. Neurol. 51, 726-729 (1994).
71. Jordan, M. A., Thrower, D. & Wilson, L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res. 51, 2212-2222 (1991). First demonstration that antimitotic mechanism of Vinca alkaloids does not require microtubule depolymerization.
72. Bai, R. B., Pettit, G. R. & Hamel, E. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and Vinca alkaloid sites. J. Biol. Chem. 265, 17141-17149 (1990).
73. Wilson, L., Jordan, M. A., Morse, A. & Margolis, R. L. Interaction of vinblastine with steady-state microtubules in vitro. J. Mol. Biol. 159, 129-149 (1982).
74. Jordan, M. A. & Wilson, L. Kinetic analysis of tubulin exchange at microtubule ends at low vinblastine concentrations. Biochemistry 29, 2730-2739 (1990).
75. Na, G. C. & Timasheff, S. N. Thermodynamic linkage between tubulin self-association and the binding of vinblastine. Biochemistry 19, 1347-1354 (1980).
76. Na, G. C. & Timasheff, S. N. Stoichiometry of the vinblastine-induced self-association of calf brain tubulin. Biochem. Soc. Trans. 8, 1347-1354 (1980).
77. Lobert, S. & Correia, J. in Methods in Enzymology Vol. 323, (ed. Johnson, M.) 77-103 (Academic Press, 2000).
78. Jordan, M. A., Margolis, R. L., Himes, R. H. & Wilson, L. Identification of a distinct class of vinblastine binding sites on microtubules. J. Mol. Biol. 187, 61-73 (1986).
79. Singer, W. D., Jordan, M. A., Wilson, L. & Himes, R. H. Binding of vinblastine to stabilized microtubules. Mol. Pharmacol. 36, 366-370 (1989).
80. Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P. & McPhail, A. T. J. Am. Chem. Soc. 93, 2325-2327 (1971).
81. Schiff, P. B., Fant, J. & Horwitz, S. B. Promotion of microtubule assembly in vitro by taxol. Nature 277, 665-667 (1979). Classic demonstration that paclitaxel enhances microtubule polymerization and stabilizes microtubules.
82. Horwitz, S. B. How to make taxol from scratch. Nature 367, 593-594 (1994).
83. Von Hoff, D. D. The taxoids: same roots, different drugs. Semin. Oncol. 24 (4 Suppl. 13), S13-3-S13-10 (1997).
84. Markman, M. Managing taxane toxicities. Support Care Cancer 11, 144-147 (2003).
85. Nogales, E., Wolf, S. G., Khan, I. A., Luduena, R. F. & Downing, K. A. Structure of tubulin at 6.5 Å and location of the taxol-binding site. Nature 375, 424-427 (1995). First high-resolution determination of the structure of polymerized tubulin and the paclitaxel-binding site.
86. Derry, W. B., Wilson, L. & Jordan, M. A. Substoichiometric binding of taxol suppresses microtubule dynamics. Biochemistry 34, 2203-2211 (1995). Mechanistic analysis of suppression of microtubule dynamics by paclitaxel.
87. Kelling, J., Sullivan, K., Wilson, L. & Jordan, M. A. Suppression of centromere dynamics by taxol in living osteosarcoma cells. Cancer Res. 63, 2794-2801 (2003).
88. Pryor, D. E. et al. The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry 41, 9109-9115 (2002).
89. Hastie, S. B. Interactions of colchicine with tubulin. Pharmacol. Ther. 512, 377-401 (1991).
90. Skoufias, D. & Wilson, L. Mechanism of inhibition of microtubule polymerization by colchicine: inhibitory potencies of unliganded colchicine and tubulin-colchicine complexes. Biochemistry 31, 738-746 (1992).
91. Tozer, G. M., Kanthou, C., Parkins, C. S. & Hill, S. A. The biology of the combretastatins as tumour vascular targeting agents. Int. J. Exp. Pathol. 63, 21-38 (2002). Review of mechanism of action of combretastatins and their therapeutic potential.
92. Kanthou, C. & Tozer, G. M. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99, 2060-2069 (2002).
93. Tozer, G. M. et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res. 61, 6413-6422 (2001).
94. Prise, V. E., Honess, D. J., Stratford, M. R., Wilson, J. & Tozer, G. M. The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int. J. Oncol. 21, 717-726 (2002).
95. Davis, P. D. et al. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res. 62, 7247-7253 (2002).
96. Dumontet, C. & Sikic, B. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J. Clin. Oncol. 17, 1061-1070 (1999).
97. Ambudkar, S. V., Kimchi-Sarfaty, C., Sauna, Z. E. & Gottesman, M. M. P-glycoprotein: from genomics to mechanism. Oncogene 22, 7468-7485 (2003).
98. Safa, A. R. Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators. Curr. Med. Chem. Anti-Canc. Agents 4, 1-17 (2004).
99. Thomas, H. & Coley, H. M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 10, 159-165 (2003).
100. Geney, R., Ungureanu, M., Li, D. & Ojima, I. Overcoming multidrug resistance in taxane chemotherapy. Clin. Chem. Lab. Med. 40, 918-925 (2002).
101. Orr, G. A., Verdier-Pinard, P., McDaid, H. & Horwitz, S. B. Mechanisms of taxol resistance related to microtubules. Oncogene 22, 7280-7295 (2003). Comprehensive review of microtubule-related mechanisms of paclitaxel resistance.
102. Kavallaris, M. et al. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res. 61, 5803-5809 (2001).
103. Minotti, A. M., Barlow, S. B. & Cabral, F. Resistance to antimitotic drugs in Chinese hamster ovary cells correlated with changes in the level of polymerized tubulin. J. Biol. Chem. 266, 3987-3994 (1991).
104. James, S. W., Sifflow, C. D., Stroom, P. & Lefebvre, P. A. A mutation in the α1-tubulin gene of Chlamydomonas reinhardtii confers resistance to anti-microtubule herbicides. J. Cell Sci. 106, 209-218 (1993).
105. Lee, W.-P. Purification and characterization of tubulin from parental and vincristine-resistant HOB1 lymphoma cells. Arch. Biochem. Biophys. 319, 498-503 (1995).
106. Ohta, S. et al. Characterization of a taxol-resistant human small-cell lung cancer cell line. Jpn. J. Cancer Res. 85, 290-297 (1994).
107. Laing, N. M. et al. Amplification of the ATP-binding cassette 2 transporter gene is functionally linked with enhanced efflux of estramustine in ovarian carcinoma cells. Cancer Res. 58, 1332-1337 (1998).
108. Burkhart, C. A., Kavallaris, M. & Band Horwitz, S. The role of β-tubulin isotypes in resistance to antimitotic drugs. Biochim. Biophys. Acta. 2, O1-O9 (2001).
109. Dumontet, C. et al. Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant is associated with altered tubulin expression Elec. J. Oncol. 2, 33-44 (1999).
110. Giannakakou, P. et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc. Natl Acad. Sci. USA 97, 2904-2909 (2000).
111. Goncalves, A. et al. Resistance to taxol in lung cancer cells associated with increased microtubule dynamics. Proc. Natl Acad. Sci. USA 98, 11737-11741 (2001). First demonstration of sensitivity of mitotic progression to precise regulation of microtubule dynamics and of the association of increased microtubule dynamics with paclitaxel resistance.
112. Haber, M. et al. Altered expression of Mβ2, the class II β-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. J. Biol. Chem. 270, 31269-31275 (1995).
113. Jaffrezou, J.-P. et al. Novel mechanism of resistance to paclitaxel in human K562 leukemia cells by combined selection with PSC833. Oncology Res. 7, 517-527 (1995).
114. Kavallaris, M. et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J. Clin. Invest. 100, 1-12 (1997).
115. Poruchynsky, M. S. et al. Accompanying protein alterations in malignant cells with a microtubule- polymerizing drug-resistance phenotype and a primary resistance mechanism. Biochem. Pharmacol. 62, 1469-1480 (2001).
116. Ranganathan, S. et al. Increase of βIII- and βIVa-tubulin isotypes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res. 56, 2584-2589 (1996).
117. Verdier-Pinard, P. et al. Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry. Biochemistry 42, 5349-5357 (2003).
118. Kavallaris, M., Burkhardt, C. A. & Horwitz, S. B. Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol. Br. J. Cancer 80, 1020-1025 (1999).
119. Martello, L. A. et al. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. Clin. Cancer Res. 6, 1978-1987 (2000).
120. Martello, L. A. et al. Elevated levels of microtubule destabilizing factors in a taxol-resistant/dependent A549 cell line with an α-tubulin mutation. Cancer Res. 63, 1207-1213 (2003).
121. Wendell, K. L., Wilson, L. & Jordan, M. A. Mitotic block in HeLa cells by vinblastine: ultrastructural changes in kinetochore-microtubule attachment and in centrosomes. J. Cell Sci. 104, 261-274 (1993).
122. Panda, D., Miller, H., Islam, K. & Wilson, L. Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action. Proc. Natl Acad. Sci. USA 94, 10560-10564 (1997).
123. Seidman, A., Scher, H. I., Petrylak, D., Derrshaw, D. D. & Curley, T. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J. Urol. 147, 931-934 (1992).
124. Hudes, G. R. et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J. Clin. Oncol. 10, 1754-1761 (1992).
125. Hudes, G. R. et al. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin. Oncol. 22, 41-45 (1995).
126. Knick, V. C., Eberwein, D. & Miller, C. Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells. J. Natl Cancer Inst. 87, 1072-1077 (1995).
127. Photiou, A., Shah, P., Leong, L., Moss, J. & Retsas, S. In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines. Eur. J. Cancer 33, 463-470 (1997).
128. Dieras, V. et al. Docetaxel in combination with doxorubicin or vinorelbine. Eur. J. Cancer 33 (Suppl 7), 20-22 (1997).
129. Garcia, P., Braguer, D., Carles, G. & Briand, C. Simultaneous combination of microtubule depolymerizing and stabilizing agents acts at low doses. Anticancer Drugs 6, 533-544 (1995).
130. Giannakakou, P., Villalba, L., Li, H., Poruchynsky, M. & Fojo, T. Combinations of paclitaxel and vinblastine and their effects on tubulin polymerization and cellular cytotoxicity: characterization of a synergistic schedule. Int. J. Cancer 75, 57-63 (1998).
131. Duflos, A., Kruczynski, A. & Barret, J.-M. Novel aspects of natural and modified Vinca alkaloids. Curr. Med. Chem. Anti-Canc. Agents 2, 55-70 (2002).
132. Plosker, G. L. & Figgitt, D. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 63, 803-843 (2003).
133. Sandler, A. B. Chemotherapy for small cell lung cancer. Semin. Oncol. 30, 9-25 (2003).
134. Armitage, J. O. Overview of rational and individualized therapeutic strategies for non-Hodgkin's lymphomas. Clin. Lymphoma 3, S5-S11 (2002).
135. Jassem, J. et al. Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer. Ann. Oncol. 14, 1634-1639 (2003).
136. Rossi, A. et al. Single agent vinorelbine as first-line chemotherapy in elderly patients with advanced breast cancer. Anticancer Res. 23, 1657-1664 (2003).
137. Seidman, A. D. Monotherapy options in the management of metastatic breast cancer. Semin. Oncol. 30, 6-10 (2003).
138. Okouneva, T., Hill, B. T., Wilson, L. & Jordan, M. A. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol. Cancer Ther. 2, 427-436 (2003).
139. Panda, D. et al. Interaction of the antitumor compound cryptophycin-52 with tubulin. Biochemistry 39, 14121-14127 (2000).
140. Kerksiek, K., Mejillano, M. R., Schwartz, R. E., Georg, G. I. & Himes, R. H. Interaction of cryptophycin 1 with tubulin and microtubules. FEBS Lett. 377, 59-61 (1995).
141. Bai, R. B. et al. Halichondrin B and homohalichondrin B, marine natural products binding in the Vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J. Biol. Chem. 266, 15882-15889 (1991).
142. Luduena, R. F., Roach, M. C., Prasad, V. & Pettit, G. R. Interaction of halichondrin B and homohalichondrin B with bovine brain tubulin. Biochem. Pharmacol. 45, 421-427 (1993).
143. Towle, M. J. et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogs of halichondrin B. Cancer Res. 61, 1013-1021 (2001).
144. Hamel, E. Natural products which interact with tubulin in the Vinca domain: maytansine, rhizoxin, phomopsin A, Dolastatins 10 and 15 and halichondrin B. Pharmacol. Ther. 55, 31-51 (1992).
145. Bai, R., Durso, N. A., Sackett, D. L. & Hamel, E. Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1. Biochemistry 38, 14302-14310 (1999).
146. Loganzo, F. et al. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res. 63, 1838-1845 (2003).
147. Hamel, E. et al. Antitumor 2,3-dihydro-2-(aryl)-4(1H)-quinazolinone derivatives. Interactions with tubulin. Biochem. Pharmacol. 51, 53-59 (1996).
148. Mabjeesh, N. J. et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3, 363-375 (2003).
149. Lakhani, N. J., Sarkar, M. A., Venitz, J. & Figg, W. D. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 23, 165-172 (2003).
150. Yoshimatsu, K., Yamaguchi, A., Yoshino, H., Koyanagi, N. & Kitoh, K. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res. 57, 3208-3213 (1997).
151. Manfredi, J. J., Parness, J. & Horwitz, S. B. Taxol binds to cell microtubules. J. Cell Biol. 94, 688-696 (1982).
152. Parness, J. & Horwitz, S. B. Taxol binds to polymerized tubulin in vitro. J. Cell Biol. 91, 479-487 (1981).
153. Diaz, J. F. & Andreu, J. M. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 32, 2747-2755 (1993).
154. Belani, C. P., Langer, C.; TAX 326 Study Group. First-line chemotherapy for NSCLC: an overview of relevant trials. Lung Cancer 38 (Suppl. 4), 13-19 (2002).
155. Fossella, F. V., Lynch, T. & Shepherd, F. A. Second line chemotherapy for NSCLC: establishing a gold standard. Lung Cancer 38, 5-12 (2002).
156. Bollag, D. M. et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 55, 2325-2333 (1995).
157. Wartmann, M. & Altmann, K. H. The biology and medicinal chemistry of epothilones. Curr. Med. Chem. Anti-Canc. Agents 2, 123-148 (2002).
158. Lee, F. Y. et al. BMS-247550: a novel epothilone analog with a mode of action similar to apclitaxel but possessing superior sntiumor efficacy. Clin. Cancer Res. 7, 1429-1437 (2001).
159. Kamath, K. & Jordan, M. A. Suppression of microtubule dynamics by epothilone B in living MCF7 cells. Cancer Res. 63, 6026-6031 (2003).
160. ter Haar, E. et al. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. Biochemistry 35, 243-250 (1996).
161. Honore, S, et al. Suppression of microtubule dynamics by discodermolide by a novel mechanism is associated with mitotic arrest and inhibition of tumor cell proliferation. Mol. Cancer Ther. 2, 1303-1311 (2003).
162. Hung, D. T., Chen, J. & Schreiber, S. L. (+)-Discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks taxol binding and results in mitotic arrest. Chem. Biol. 3, 287-293 (1996).
163. Kavallaris, M., Verrills, N. M. & Hill, B. T. Anticancer therapy with novel tubulin-interacting drugs. Drug Resist. Update 4, 392-401 (2001).
164. Kowalski, R. J. et al. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol. Pharmacol. 52, 613-622 (1997).
165. Smaletz, O. et al. Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. Ann. Oncol. 14, 1518-1524 (2003).
166. Kelly, W. et al. Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer. Clin. Cancer Res. 9, 2098-2107 (2003).
167. Hudes, G. et al. Phase I clinical and pharmacologic trial of intravenous estramustine phosphate. J. Clin. Oncol. 20, 1115-1127 (2002).
168. Dahllof, B., Billstron, A., Cabral, F. & Hartley-Asp, B. Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res. 53, 4573-4581 (1993).